

## Learning Objectives

After completion of this course, the learner will be able to:

- Identify key components of a clinical research budget
- Increase your confidence level in supporting the budget negotiation process with a corporate clinical research sponsor



### MUSC Clinical Research Liaisons

The Office of Clinical Research welcomes any feedback or suggestions from our clinical research collaborators.

### Signe Denmark, MS, CCRP

Associate Director, Research Opportunities & Collaborations 843.792.4146

denmarks@musc.edu

### Amanda Cameron, MPH, CPH, CCRP

Program Manager, Research Opportunities & Collaborations 843.792.3131

cameroa@musc.edu





# Contract Research Organization (CRO) Strategic Partnerships











## **Budgeting Process**

Feasibility & Planning

Sponsor & Internal Feasibility

Prospective Reimbursement Analysis

Who will pay for protocol procedures?

Internal Budget Development

Personnel, per patient costs, site level


Budget Negotiation

Negotiations and justification

ePDS & Contract Negotiation / Execution

Internal routing & approvals





### How many patients do we have?

- > How many will qualify considering protocol inclusion/exclusion?
  - > Self-service patient count tools (Epic SlicerDicer, MUSC i2b2)
  - > Patient registries (Hollings, other)
- > How many patients will you need to approach?
- Anticipated screen failure rate?
- Anticipated drop out rate?



## How many patients is the sponsor expecting?

- > What will be in the contract/informed consent?
- Is the target realistic?
- > Poor enrollment = bad value for the sponsor
- > It is better to meet your contracted number and request to amend the contract than to over promise and under deliver!



## Self-Service Query Tools





i2b2 Query & Analysis Tool



# Self-Service Research Data & Feasibility Consultation Service



South Carolina Clinical & Translational Research Institute





Login / Sign Up

SPARCRequest SPARCDashboard SPARCInfo STEP 1 STEP 3: STEP 6: Milestones & Add/Update **Review Your** Calendar Structure Services Request STEP 1: Add/Update Services Browse Service Catalog My Services feasibility Completed Medical University of South Self-Service Research Data & Feasibility Self-Service Research Data & Feasibility SCTR's Research Data Access & Feasibility team can help you navigate the process of Self-Service Research Data Effectiveness and Data Analytics Research Resource accessing clinical data to evaluate your study's feasibility. Our consultative meeting topics include & Feasibility Consultation research feasibility considerations, data access needs, research data request services, and/or study-specific guidance using our self-service tools: Epic's SlicerDicer and CDW Research Query Tool. The team will also work to discuss a myriad of other feasibility considerations and facilitate matching to other service providers, as needed for successful implementation of your study. Center for Genomics Self-Service Research Data & Feasibility Consultation Show Details ClinCard by Greenphire Continue News **Calendar** Help/FAQs Center for Biomedical Imaging(CBI) SPARC OS \_Operations Services Now Available In Review Feedback 3:00 PM - 4:00 PM **SPARCRequest** National Center of Show Details Jul 10, 2019 Contact Us Rehabilitation (NC NM4R)

2019-2020 SCTR Technology

**Development Grants Funding Is Now** 

SPARC OS Governance:

Operations and Logistics

- Who will perform protocol related procedures, research coordination, recruitment, regulatory, store/dispense investigational product?
  - What are the personnel requirements?
  - Do we have them on staff? (i.e. Study coordinators, program assistants, etc.)
- What additional services/approvals/equipment/training may be required?



- When will the study begin and end?
  - Add additional time to the sponsor's estimate as recruitment and study duration is often longer than projected
- Where will the study be conducted, do we have the space?
- Which IRB will be utilized (local vs. central)?
- How will you reach the study's recruitment goals?
  - Clinic roster
  - Advertising
  - Epic recruitment report, BPA, etc.



### **Research Coordination & Management**

The SCTR Research Nexus provides a wide range of research coordination and management services for MUSC investigators. The research coordinator staff includes experienced, trained, and VA-credentialed personnel, as well as licensed nurse coordinators. For investigators seeking assistance with management of multi-site trials or day-to-day oversight of research programs, project management services are available.

### Services

- Study management and coordination
- Project management
- Regulatory management
- Budget development
- Data management
- Recruitment
- Invoicing and billing
- Quality assurance reviews
- Study assessments (semi-structured interviews, psychometric testing)
- Social-behavioral interventions
- Study record and drug storage for active studies
- Inpatient, outpatient, and outlying clinics, Ralph H. Johnson Veterans Administration
- Support for MUSC researchers for full, partial, or VA-funded studies

#### **SCTR Institute**

4

Research Nexus

Coordination & Management

Research Laboratory

Clinical Nursing & Nutrition

Nexus Research Center







### SCTR Research Nexus

### Phase 1-4 Research Center & Hospital Provider Based Clinic

Outpatient, Inpatient & Mobile Nursing Chemotherapy & Biotherapy Certified Nurses **Nutritionist** 



6 Examination Rooms 6 Procedure Rooms

1 Infusion Suite



Pulmonary Function Testing Suite



## SCTR Research Nexus Laboratory



Qiagen Autopure for Large Volume Automated DNA Extraction



Fume Hood for Hazardous Chemical Handling and Stool Preps



Laminar Flow Hood for PBMC Processing and Aseptic Methods



Six -80°C Freezers, One -20°C Freezer and Two 2-8°C Refrigerators



## Investigational Drug Services (IDS)

- Monday through Friday, 8AM to 4:30PM
- 6 staff
- Utilization required for inpatient studies
- All refrigerators and freezers are hooked up to back-up power and alarmed
- Temperatures are monitored remotely
  - 24 hours a day, 7 days a week
  - CheckPoint monitoring system



Prospective Reimbursement Analysis

Internal Budget Development Budget & Contract Negotiation ePDS & Contract Execution

## Who will pay for protocol procedures?

## Clinical Trials National Coverage Decision (NCD)

- Intended to extend coverage for routine clinical costs for certain qualifying clinical trials
- Prior to this directive Medicare did not pay for any costs associated with the care of patients enrolled in a clinical trial
- Encourage the participation of older Americans in clinical trials (esp. cancer)

### **Routine Costs**

- > Items and services considered conventional care
- Can include items and services for prevention, diagnosis, or treatment of complications associated with the clinical trial





Feasibility & Planning

Prospective Reimbursement Analysis

Internal Budget Development

Budget & Contract Negotiation ePDS & Contract Execution

### Routine Care vs. Research Costs

- Routine Care are services that would be provided to the patient regardless of study participation (billable to insurance)
- Non-covered services/non-routine services are procedures completed strictly for research purposes (billed to sponsor)

### Routine Care vs. Standard of Care

- > Routine Care or Conventional Care are services that are covered by Medicare
- > Standard of Care may include services not covered by Medicare

# "Physician practices should remember that 'necessary' does not always constitute 'covered'...."

OIG Compliance Program Guidance for Individual and Small Group Physician Practices (October 5, 2000)



### Risks Associated with Research Billing Non-Compliance

### Institutional clinical research billing risks:

- 1. Billing for services already paid by the sponsor (double billing)
- 2. Billing for services promised free in the informed consent
- 3. Billing for services that are for research-purposes only
- 4. Billing for services that are part of a non-qualifying clinical trial



Budget & Contract Negotiation

ePDS & Contract Execution

## Clinical Research Billing Principles

Medicare requires a <u>three-part process</u> for clinical research services coverage:

- 1. Does the study "qualify" for coverage?
- 2. What items and services are "routine costs"?
- 3. Do Medicare rules allow coverage of specific "routine costs" within a clinical trial?



# MUSC Office of Clinical Research (OCR) Prospective Reimbursement Analysis (PRA) Process

- > Informs the budgeting process
- > Sets up research billing calendar
- > Used for monitoring & auditing clinical research billing compliance
- Tool to evaluate financial status of a study

Each MUSC Department has assigned a liaison as the primary point of contact with the OCR for Prospective Reimbursement Analysis (PRA) Process



Prospective Reimbursement Analysis

Internal Budget Development

Budget & Contract Negotiation ePDS & Contract Execution

# All studies with the potential to include MUSC Health billable services will require a Prospective Reimbursement Analysis by the Office of Clinical Research

- OCR PRA team will partner with study teams to:
  - Map out research workflow
  - > Provide feasibility analysis support
  - > Build research billing calendar
  - Inform pricing for CPT coded services in study budgets
  - > Ensure billing compliance harmonization of documents
- Oncology trials will be included after initial May 1<sup>st</sup> phase-in


OCR PRA Service will be requested in SPARCRequest®

Regulatory and start up packet, essential documents required



## Prospective Reimbursement Analysis Service Request

### About SPARCRequest





Feasibility & Planning

Prospective Reimbursement Analysis

Internal Budget Development Budget Negotiation ePDS &
Contract
Negotiation /
Execution

# **Budget Categories**

- Site level costs
- Per subject costs
- Personnel costs
- Overhead (F&A)



## **Sponsor Budget Categories**

#### Per Subject Costs Clinical Overhead Services Per patient study staff effort Administrative start-up based assessments Institutional Review Board Examples include: (IRB) • Per patient MUSC Health • 30% Indirect Cost / Facilities Office of Clinical Research Informed consent Services & Administration (F&A) Rate Pharmacy Concomitant medications Typically CPT coded Assessed on all costs Study Maintenance procedures Questionnaires •IRB and OCR PRA fees are Close-out costs • Included in the study billing Data collection / entry only fees excluded from the plan and pushed to Epic corporate F&A rate Study Team Site Level Assessments Costs

# **Sponsor Proposal**

Procedure	Pre-Op	Operative	6 Months	1 Year	2 Years	5 Years	7 Years	10 Years
Informed Consent	\$78							
Inclusion/Exclusion Criteria	\$44							
Medical History/Demographics	\$40							
Operative (Surgical) procedure/device		\$48						
PROMIS Global Health	\$17		\$17	\$17	\$17	\$17	\$17	\$17
Ankle Osteoarthritis Score (AOS)	\$24		\$24	\$24	\$24	\$24	\$24	\$24
FAOS Questionnaire	\$18		\$18	\$18	\$18	\$18	\$18	\$18
TAR Satisfaction			\$15	\$15	\$15	\$15	\$15	\$15
Radiographic Assessment (Investigator requirement) 1	\$119		\$119	\$119	\$119	\$119	\$119	\$119
Adverse Event Assessment		\$25	\$25	\$25	\$25	\$25	\$25	\$25
Primary Investigator Fee	\$60	\$60	\$60	\$60	\$60	\$60	\$60	\$60
Study Coordinator Fee	\$48	\$48	\$48	\$48	\$48	\$48	\$48	\$48
Data Entry	\$43	\$43	\$43	\$43	\$43	\$43	\$43	\$43
One Subject								\$2,929
Site Start-Up Fee:	\$3,000							
IRB Fee	\$1,500							
IRB Renewal Fee (per year):	\$500							
Protocol Amendment (per amendment):	\$500							
Archiving Fee At Study Close:	\$500							
Site Monitoring Fee (per visit):	\$384							
Site Close-Out Fee:	\$500							
Serious Adverse Event (per event):	\$100							
X-Rays (Outside standard of care):	\$76							
Unscheduled visits as described in the protocol and	1							
will be paid based on CRF deliverable as provided in								
the fee schedule above								
	_							



## Internal Budget Categories

- Administrative start-up
- Institutional Review Board (IRB)
- Office of Clinical Research
- Pharmacy
- Study Maintenance
- Close-out costs

Site Level Costs

### Per Subject Costs

- MUSC Health Clinical Services
- Ancillary Service Provider Costs
- Nexus
- SCTR's Research Coordination & Management

- Study team no salary cap
- PI
- Co-Investigators
- Study Coordinators
- Data Coordinator
- Regulatory Specialist

Personnel Costs

### Overhead

- 30% Indirect Cost / Facilities & Administration (F&A) Rate
- Assessed on all costs
- •IRB and OCR PRA fees are only fees excluded from the corporate F&A rate



## Site Level Costs - Start-up

These are the charges for activities spent getting a study up and running

If there is no budget agreement & contract, you will not be paid

Most of the budget captures time spent

- > Protocol review
- > Preparing a budget
- > Regulatory submission (IRB forms)
- > Pharmacy review and setup



## Site Level Costs - Other

In addition to startup there are other site level costs. Study maintenance costs, such as:

- > Freezer storage
- > Record storage
- Monitor change fee
- Close out costs
- > Etc.

These are often listed itemized as invoiceable costs





## Site Level Costs


These are the charges for activities spent getting a study up and running and study maintenance

- Start-up
- Service provider fees
  - Institutional Review Board (IRB) fees
  - Prospective Reimbursement Analysis (PRA) fees
  - Investigational Drug Services (IDS) fees
  - Radiology Review fees
- Per patient invoiceable items
- Study maintenance costs
- Close out costs

For more justification information, visit the Office of Clinical Research on the horseshoe <a href="here">here</a>

### About SPARCRequest









## Site Level Costs - First Round


			Sponsor Unit		<b>Procedure</b>			
			Cost (Negotiated	Research Cost	Occurence	F&A	Total Cost to	<b>Margin to Cover</b>
Other Services		Service Rate	Reimbursement)	(Your Cost)	(N)	Applies?	Sponsor (+OH)	Personnel Effort
Study Level Services (Pass Through)								
Prospective Reimbursement Analysis (0002)	(	\$ 2,000.00	\$ 2,000.00	\$ 2,000.00	1	N	\$ 2,000.00	\$ -
Prospective Reimbursement Analysis Amendmen	t Fee	\$ 500.00	\$ 500.00	\$ 500.00	1	N	\$ 500.00	\$ -
Study Start-Up Fee/Site Set-Up Fee (0005)	5	\$ 9,540.00	\$ 9,540.00	\$ -	1	Υ	\$ 12,402.00	\$ 9,540.00
Annual Study Maintenance Fee (billing compliance	, sponsor/CRO correspondence, ongoing patient	\$ 5,544.00	\$ 5,544.00	\$ -	11	Υ	\$ 79,279.20	\$ 60,984.00
Daily Monitoring Visit Fee (0005)	\$	\$ 804.00	\$ 804.00	\$ -	12	Υ	\$ 12,542.40	\$ 9,648.00
IRB Document Study Team Preparation Fee for Ar	mendments, Continuing Reviews, Termination (0.5	\$ 582.00	\$ 582.00	\$ -	1	Υ	\$ 756.60	\$ 582.00
Site Audit, Quality Audit, Clinical Trial Master File A	udit (0005)	\$ 2,118.00	\$ 2,118.00	\$ -	1	Υ	\$ 2,753.40	\$ 2,118.00
Document Storage, Archiving Total Cost (0005)		\$ 1,200.00	\$ 1,200.00	\$ -	1	Υ	\$ 1,560.00	\$ 1,200.00
Study Close Out: Including All Activities Related to	Closing Out the Site (0005)	\$ 1,740.00	\$ 1,740.00	\$ -	1	Y	\$ 2,262.00	\$ 1,740.00
Initial Protocol Review (0006)	\$	\$ 2,500.00	\$ 2,500.00	\$ 2,500.00	1	N	\$ 2,500.00	\$ -
Continuing Review (0006)	5	\$ 750.00	\$ 750.00	\$ 750.00	11	N	\$ 8,250.00	\$ -
IRB Amendment (0006)	5	\$ 500.00	\$ 500.00	\$ 500.00	1	N	\$ 500.00	\$ -
Imaging Protocol Review (Level 1) (0009)		\$ 300.00	\$ 300.00	\$ 300.00	1	Υ	\$ 390.00	\$ -
Serious adverse events (SAE)	9	\$ 348.00	\$ 348.00	\$ -	1	Υ	\$ 452.40	\$ 348.00
Study Level Services: Total Cost							\$ 126,148.00	\$ 86,160.00



## Site Level Costs – Final

ner Services			Sponsor Unit Cost (Negotiated Reimbursement)		Procedure Occurence (N)	F&A Applies		Margin to Cover Personnel Effort	
Study Level Services (Pass Through)	36	I VICE IXALE	Reinibursement	(Tour Cost)	Occurence (IV)	•	Sponsor (1011)	T ersonner Enort	
Prospective Reimbursement Analysis (0002) -									
fee not accepted by sponsor	S	2.000.00	\$ -	\$ 2,000.00	1	N	\$ -	\$ -2.000.00	
Clinical Research Fee - will cover most of the		_,						,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
OCR PRA fee	\$	_	\$ 1,528.00	\$ -	1	N	\$ 1,528.00	\$ 1,528.00	
Study Start-Up Fee/Site Set-Up Fee (0005)	\$	9,540.00	\$ 3,860.00	\$ -	1	Υ	\$ 5,018.00		
Administrative Fee (billing compliance, sponsor/CRO correspondence, ongoing patient	screening/r \$	5,544.00	\$ 2,000.00	\$ -	1	Υ	\$ 2,600.00	\$ 2,000.00	
Daily Monitoring Visit Fee (0005)	\$	804.00	\$ 804.00	\$ -	12	Υ	\$ 12,542.40	\$ 9,648.00	
IRB Document Study Team Preparation Fee for Amendments, Continuing Reviews, Te	rmination (0\$	582.00	\$ 580.00	\$ -	12	Υ	\$ 9,048.00	\$ 6,960.00	
Site Audit, Quality Audit, Clinical Trial Master File Audit (0005)	\$	2,118.00	\$ 1,650.00	\$ -	1	Υ	\$ 2,145.00	\$ 1,650.00	
Document Storage, Archiving Total Cost (0005)	\$	1,200.00	\$ 771.50	\$ -	1	Υ	\$ 1,002.95	\$ 771.50	
Study Close Out: Including All Activities Related to Closing Out the Site (0005)	\$	1,740.00	\$ 1,100.00	\$ -	1	Υ	\$ 1,430.00	\$ 1,100.00	
Initial Protocol Review (0006)	\$	2,500.00	\$ 2,500.00	\$ 2,500.00	1	N	\$ 2,500.00	\$ -	
Continuing Review (0006)	\$	750.00	\$ 750.00	\$ 750.00	11	N	\$ 8,250.00	\$ -	
IRB Amendment (0006)	\$	500.00	\$ 500.00	\$ 500.00	1	N	\$ 500.00	\$ -	
Imaging Protocol Review (Level 1) \$428 of this fee will go to OCR PRA	\$	300.00	\$ 629.00	\$ 300.00	1	Υ	\$ 817.70	\$ 329.00	
Obtain copies of diagnostic films, X-rays	\$	76.00	\$ 76.00	\$ -	1	Υ	\$ 98.80	\$ 76.00	
Serious adverse events (SAE)	\$	348.00	\$ 200.00	\$ -	1	Y	\$ 260.00	\$ 200.00	
Study Level Services: Total Cost							\$ 47,740.85	\$ 26,122.50	





## Per Subject Costs: Events During Study

#### SCHEDULE of EVENTS

Procedures	Pre-op	Op.	6 mo +/-30 days	1 yr +/-60 days	2 yr +/-60 days	5 yr +/-60 days	7 yr +/-60 days	10 yr +/-60 days	Study Close
Informed Consent	X								
Inclusion/Exclusion Criteria	X								
Medical History/Demographics	х								
Operative (Surgical) procedure/device		X							
PROMIS Global Health	X		X	X	X	X	X	X	
Ankle Osteoarthritis Score (AOS)	х		X	Х	Х	X	Х	Х	
FAOS Questionnaire	X		X	Х	Х	X	Х	X	
Total Ankle Replacement Satisfaction			X	X	Х	Х	Х	X	
Radiographic Assessment (Investigator requirement)	Х		X	Х	X	X	Х	Х	
Adverse Event Assessment			X	X	X	X	X	X	
End of Study				1					X
Surgical Intervention <sup>1</sup>									
*Sponsor-approved Unscheduled Visit <sup>2</sup>									


<sup>1&</sup>amp;2 These are not scheduled time point events but will be observed for throughout study participation.



## Per Subject Costs

- CPT Coded Procedures: work with OCR PRA team
- Informed Consent
- Retention activities
- Weight / vital signs
- Demographics
- Questionnaires
- Patient remuneration + fees
- Adverse event reporting (AE)
- Blood draws
- Labs, PK samples
- Shipping Samples

#### **About SPARCRequest**





## Per Patient Costs – 1<sup>st</sup> Round

Selected Services	CPT Code	Service Date	Cost (Negotiated Reimbursement)	Research Cos (Your Cost)	t # of Subjects	Pre-op	Operativ	e 6 monti	ı 1 Year	2 Year	r 5 Year	r 7 Yea	r 10 Vea	Unit Cost P		
TAR	CI I Code	Service Itale	Reillibursellierity	(Tour Cost)	Subjects	-14	Operativ	180	365	730	1825			I I auciit	ı au	ent
IAK						-14 R						T R	T R	_		
Study Team Assessments(0005)						K	1 1	I K	ı ĸ	1 K	1 1	I K	ı K	•		
nformed Consent		\$ 174.00	\$ 174.00	\$ -	20	1								\$ 174	.00 \$	
nclusion/Exclusion Criteria		\$ 117.00			20	1									.00 \$	
Medical History with Demographics		\$ 117.00			20	1									.00 \$	
Operative (Surgical) Data Collection		\$ 57.00			20		1								.00 \$	
Quality of Life Questionnaire, General (QOL)		\$ 46.00			20	1	•	1	1	1	1	1	1		.00 \$	
Osteoarthritis Pain Intensity Visual Analog Scale		\$ 30.00			20	1		1	1	1	1	1	1		.00 \$	_
Orthopaedic Outcome Score Questionnaire		\$ 46.00		-	20	1		1	1	1	1	1	1		.00 \$	
Device/Medication Satisfaction Assessment		\$ 29.00			20			1	1	1	1	1	1		.00 \$	
nvestigator Radiographic Assessment Data Collection		\$ 120.00			20	1		1	1	1	1	1	1		.00 \$	_
Adverse Events		\$ 81.00			20	· ·	1	1	1	1	1	1	1		.00 \$	
Physician-Per Hour		\$ 240.00			20	1	1	1	1	1	1	1	1		.00 \$	_
Study Coordinator-Per Hour		\$ 114.00			20	1	1	1	1	1	1	1	1		.00 \$	_
Data Entry-Per Hour		\$ 58.00		-	20	1	1	1	1	1	1	1	1		.00 \$	_
Research Device (0010)																
Device		<b>S</b> -	s -	\$ -	20		1							\$	\$	
Radiology (PB-Outreach)(0011)					20											
	73610	\$ 162.00	\$ 162.00	\$ 8.63	2 20		1		1	1	1	1	1	1 \$	S	_
NIO A-IVAT ANICE 5: VVV	73010	¥ 102.00	Ψ 102.00	Ψ 0.02	20		•		•	•		1	•	1 9	u u	
Total per Patient per Visit (-OH)						\$1.062.00	\$550.00	\$764.00	\$764.00	\$764.00	\$764.00	\$764.00	\$764.00	\$ 6,196	00	
Total Overhead Cost per Visit						\$ 318.60	\$165.00	\$229.20	\$ 229.20	\$229.20	\$229.20	\$ 229.20		\$ 1.858		
Total per Patient per Visit (+OH)						\$1,380.60	\$715.00	\$993.20	\$993.20	\$993.20	\$993.20	\$ 993.20		\$ 8,054		
Total Margin per Patient per Visit						\$1,062.00	\$550.00	\$764.00	\$764.00	\$764.00	\$764.00	\$764.00		0,004	.00	
Total Margin per Study for per Patient Assessments	¢ 422 020 00					\$ 1,002.00	\$ 550.00	\$ 704.00	\$ 704.00	\$704.00	\$ 704.00	\$ 704.00	\$704.00			
total margin per study for per Patient Assessments	\$ 123,520.00															
TAR: Summary																
			<b>6</b> 0.400.00													
TAR: Total Cost (-OH) per Patient			\$ 6,196.00													
TAR: Total Cost (+OH) per Patient			\$ 8,054.80													
TAR: Total Margin per Patient			\$ 6,196.00													
			4750/													
MUSC increase over sponsor initial offer			175%													



# Per Patient Costs – Final

			Sponsor Unit											Total Sponsor	Total Research
			Cost (Negotiated	Research Cost	# of									Unit Cost Per	Cost Per
Selected Services	CPT Code	Service Rate	Reimbursement)	(Your Cost)	Subjects	Pre-op	Operativ	e 6 mon	th 1 Yea	r 2 Yea	ır 5 Yeaı	r 7 Year	10 Year	Patient	Patient
ITAR						-14	0	180	365	730	1825	2555	3650		
						R	T R	T R	T R	T R	T R	T R	ΓR	Т	
Study Team Assessments(0005)															
Informed Consent		\$ 174.00	\$ 125.00	\$ -	20	1								\$ 125.00	\$ -
Inclusion/Exclusion Criteria		\$ 117.00	\$ 117.00	\$ -	20	1								\$ 117.00	\$ -
Medical History with Demographics		\$ 117.00	\$ 50.00	\$ -	20	1								\$ 50.00	\$ -
Operative (Surgical) Data Collection		\$ 57.00	\$ 57.00	\$ -	20		1							\$ 57.00	\$ -
Quality of Life Questionnaire, General (QOL)		\$ 46.00	\$ 36.00	\$ -	20	1		1	1	1	1	1	1	\$ 252.00	\$ -
Osteoarthritis Pain Intensity Visual Analog Scale		\$ 30.00	\$ 30.00	\$ -	20	1		1	1	1	1	1	1	\$ 210.00	\$ -
Orthopaedic Outcome Score Questionnaire		\$ 46.00	\$ 25.00	\$ -	20	1		1	1	1	1	1	1	\$ 175.00	\$ -
Device/Medication Satisfaction Assessment		\$ 29.00	\$ 29.00	\$ -	20			1	1	1	1	1	1	\$ 174.00	\$ -
Investigator Radiographic Assessment Data Collection		\$ 120.00			20	1		1	1	1	1	1	1	\$ 840.00	\$ -
Adverse Events		\$ 81.00	\$ 28.00	\$ -	20		1	1	1	1	1	1	1	\$ 196.00	\$ -
Physician- (half hour alloted for this study)		\$ 240.00	\$ 104.50	\$ -	20	1	1	1	1	1	1	1	1	\$ 836.00	\$ -
Study Coordinator		\$ 114.00			20	1	1	1	1	1	1	1	1	\$ 464.00	\$ -
Data Entry-Per Hour		\$ 58.00	\$ 52.00	\$ -	20	1	1	1	1	1	1	1	1	\$ 416.00	\$ -
Research Device (0010)															
Device		\$ -	\$ -	\$ -	20		1							\$ -	\$ -
Radiology (PB-Outreach)(0011)															
CHG X-RAY ANKLE 3+ VW	73610	\$ 162.00	\$ 162.00	\$ 8.62	20		1		1	1	1	1		1 \$ -	\$ -
Total per Patient per Visit (-OH)						\$ 717.50	\$299.50	\$482.50	\$482.50	\$482.50	\$482.50	\$482.50	\$482.50	\$ 3,912.00	
Total Overhead Cost per Visit						\$ 215.25	\$ 89.85	\$144.75	\$144.75	\$144.75	\$144.75	\$144.75	\$144.75	\$ 1,173.60	
Total per Patient per Visit (+OH)						\$ 932.75	\$389.35	\$627.25	\$627.25	\$627.25	\$627.25	\$627.25	\$627.25	\$ 5,085.60	
Total Margin per Patient per Visit						\$ 717.50	\$299.50	\$482.50	\$482.50	\$482.50	\$482.50	\$482.50	\$482.50		
Total Margin per Study for per Patient Assessments	\$ 78,240.00														
ITAR: Summary															
ITAR: Total Cost (-OH) per Patient			\$ 3,912.00												
ITAR: Total Cost (+OH) per Patient			\$ 5,085.60												
ITAR: Total Margin per Patient			\$ 3,912.00												
,			,												
MUSC increase over sponsor initial offer			74%												
·															



### Service Rate versus Your Cost

- For industry funded studies, typically request full price of a service
- Difference between full cost and research rate for services can be applied to effort/personnel costs
- Remaining funds on an industry sponsored study are research contingency/development funds
- Example: ankle X-ray CPT code 73610
  - Service rate \$162 = fee sponsor pays site for the service
  - Your cost \$8.62 = research bill study will pay
  - Difference \$153.38 = personnel costs/contingency funds



### **Personnel Costs**

#### Study Team

- > PI
- Co-Investigators
- Study Nurse
- > Study Coordinator(s)
- > Data Coordinator
- > Program Assistants

#### Administration

- > Billing/Finance Manager
- > Regulatory Coordinator



# Considerations for estimating time

- Pre-screening: how complicated are the inclusion/exclusion criteria?
- Informed consent
  - > Estimate time to answer questions
  - Length of Informed Consent Document
  - Legally Authorized Representative (LAR) will take additional time
- Medical history: How big is the medical record?
- Surveys: Will the patient be able to read the entire survey?
- Drug administration: How complicated is the drug delivery?
- Visit prep and scheduling: Are there additional appointments needed?
- Specimen handling: Review the instructions carefully
- Data entry: Are data entered electronically?
- General considerations: Are you including pediatric patients?



# **Personnel Costs**

ITAR									
INFINITY Total Ankle Replacement Follow-	-up (ITAR)								
ABC Medical Supply									
Minnie Mouse									
Tinker Bell									
Industry-Initiated/Industry-Sponsored									
30%									
38.4%									
Role	Instit	tutional Base	% Effort	Project Period	(ii Sala	ry Requeste	Fringe	Total	
Primary PI	\$	225,000.00	0.5%	144	\$	13,500.00	\$ 5,184.00	\$	18,684.00
Research Assistant/Coordinator	\$	38,000.00	10%	144	\$	45,600.00	\$17,510.40	\$	63,110.40
General Access User	\$	-	0%	144	\$	-	\$ -	\$	-
					\$	59.100.00	\$ 22 694 40	\$	81,794,40
	INFINITY Total Ankle Replacement Follow- ABC Medical Supply Minnie Mouse Tinker Bell Industry-Initiated/Industry-Sponsored 30% 38.4%  Role Primary PI Research Assistant/Coordinator	INFINITY Total Ankle Replacement Follow-up (ITAR)  ABC Medical Supply  Minnie Mouse  Tinker Bell  Industry-Initiated/Industry-Sponsored  30%  38.4%  Role  Primary Pl  Research Assistant/Coordinator  \$ \$	INFINITY Total Ankle Replacement Follow-up (ITAR)  ABC Medical Supply  Minnie Mouse  Tinker Bell  Industry-Initiated/Industry-Sponsored  30%  38.4%  Role  Primary PI  Research Assistant/Coordinator  Institutional Base  38,000.00	INFINITY Total Ankle Replacement Follow-up (ITAR)  ABC Medical Supply  Minnie Mouse  Tinker Bell  Industry-Initiated/Industry-Sponsored  30%  38.4%  Role  Primary Pl  \$ 225,000.00  0.5%  Research Assistant/Coordinator  \$ 38,000.00  10%	INFINITY Total Ankle Replacement Follow-up (ITAR)   ABC Medical Supply	INFINITY Total Ankle Replacement Follow-up (ITAR)   ABC Medical Supply	INFINITY Total Ankle Replacement Follow-up (ITAR)   ABC Medical Supply	INFINITY Total Ankle Replacement Follow-up (ITAR)	INFINITY Total Ankle Replacement Follow-up (ITAR)



### Potential Hidden Costs

#### Time not accounted for:

- > Screening
- > Training (including investigator meeting)
- Monitor visits
- > Queries
- Serious adverse events

#### **Supplies**

Not all supplies will be provided (e.g. IV)



# **Breakeven Analysis**

#### Formula assumptions:

- > All patients complete all visits
- > Study runs within the project period
- No changes to personnel effort allocations

Study Budget	
Total Study Cost (Sponsor Cost)	\$ 149,452.85
Total Margin	\$ 104,362.50
Study Contingency	\$ 22,568.10
Breakeven Analysis	14
Total Budget	\$ 149,452.85



# Final Executed Budget in Contract

Procedure	Pre-Op	Operative	6 Months	1 Year	2 Years	5 Years	7 Years	10 Years
Informed Consent	\$162.50							
Inclusion/Exclusion Criteria	\$152.10							
Medical History/Demographics	\$65							
Operative (Surgical) procedure/device		\$74.10						
PROMIS Global Health	\$46.80		\$46.80	\$46.80	\$46.80	\$46.80	\$46.80	\$46.80
Ankle Osteoarthritis Score (AOS)	\$39		\$39	\$39	\$39	\$39	\$39	\$39
FAOS Questionnaire	\$32.50		\$32.50	\$32.50	\$32.50	\$32.50	\$32.50	\$32.50
TAR Satisfaction			\$37.70	\$37.70	\$37.70	\$37.70	\$37.70	\$37.70
Radiographic Assessment (Investigator requirement)	\$156		\$156	\$156	\$156	\$156	\$156	\$156
Adverse Event Assessment		\$36.40	\$36.40	\$36.40	\$36.40	\$36.40	\$36.40	\$36.40
Primary Investigator Fee	\$135.85	\$135.85	\$135.85	\$135.85	\$135.85	\$135.85	\$135.85	\$135.85
Study Coordinator Fee	\$75.40	\$75.40	\$75.40	\$75.40	\$75.40	\$75.40	\$75.40	\$75.40
Data Entry	\$67.60	\$67.60	\$67.60	\$67.60	\$67.60	\$67.60	\$67.60	\$67.60
One Subject								\$5085.60


All charges below (inclusive of overhead) are study requirements and will be invoiced at the time they occur.

Site Start-Up Fee:	\$5,018
Administrative Fee (billing compliance, sponsor/CRO correspondence, ongoing patient	\$2,600
screening/retention, training, administrative costs, etc.)	
Clinical Research Fee	\$1572
IRB Fee	\$2,500
IRB Renewal Fee (per year):	\$750
Protocol Amendment (per amendment):	\$500
IRB Document Study Team Preparation Fee for Amendments, Continuing Reviews,	\$754
Termination	
Radiology Set-Up Fee	\$818
Archiving Fee At Study Close:	\$1,003
Site Monitoring Fee (per visit):	\$1,045.20
Site Audit, Quality Audit, Clinical Trial Master File Audit	\$1,672
Site Close-Out Fee:	\$1,430
Serious Adverse Event (per event):	\$260
Obtain copies of diagnostic films, X-Rays	\$98.80
Unscheduled visits as described in the protocol and will be paid based on CRF deliverable	
as provided in the fee schedule above	
	l





# Case Study: Budgeting Impact





# **OCR Finance Website Resources**



Home > Research > Office of Clinical Research > Finance > Budget Negotiations

#### **Budget Negotiations**

Negotiation is the process of reaching a mutual agreement; in this case MUSC and the sponsor are agreeing on the payment terms of a contract or other legal document. During budget negotiations MUSC and the sponsor propose and counter-propose costs to arrive at a mutually agreeable budget. The objective of the negotiation process is to end up with an appropriately funded clinical research study. As you begin negotiating, it is important to be prepared and knowledgeable about the clinical research study. Advanced planning, preparation and patience are key skills in a successful negotiation.

- Internal versus Sponsor Budget: negotiate in sponsor budget format
  - Know your true costs and breakeven
  - · Leave room to negotiate/meet in the middle
- Fair Market Value (FMV)
  - · Be prepared to justify your costs
  - Justification documentation

Justification Documentation Language Examples to Support the Negotiation Process





# **Justification Documentation**

Version: 1.0 - Date: 10/23/2018



Office of Clinical Research
Office of the Vice President for Research
Suite 170, 125 Doughty Street, MSC 195
Charleston SC 29425-1750
Tel 843 792 7900
Musc-ocr@musc.edu

#### Instructions for use:

This document contains example justification documentation to support the budget negotiation process with industry sponsors for corporate clinical research studies.

When your study specific justification documentation is completed, please utilize your research department letterhead and save as a PDF to provide to the sponsor.

#### **Institutional Fees**

#### F&A Rate

An overhead rate of 30% TDC is required by the Institution in order to participate in clinical research studies. This overhead rate is charged to all Pharmaceutical Companies and Device Manufacturers for all Clinical Research Studies. The 30% is charged on all costs excluding IRB fees. The overhead is taken directly from payments received and is not part of the compensation paid to the Principal Investigator.

#### Standard Holdback Language

The standard acceptable holdback percentage for clinical research payments for industry sponsored clinical research studies in which MUSC participates is ten percent (10%).

MUSC expects that at least ninety percent (90%) of each payment due will be made under the terms of the Clinical Trial Agreement, typically upon verification of visit completion or receipt of invoice and that the balance of monies earned, up to ten percent (10%), will be paid to MUSC under the terms of the Clinical Trial Agreement, typically upon acceptance of the Case Report Forms at the end of the study.

#### Office of Research Integrity Institutional Board for Human Research (IRB) Fees

The <u>IRB Initial Protocol Review fee of \$2500</u> is charged upon initial submission for IRB review by MUSC.

The IRB Continuing Review fee of \$750 is charged annually by MUSC.



# What are Hidden Costs?

#### Time not accounted for:

- > Screening
- > Training (including investigator meeting)
- Monitor visits
- > Queries
- > Serious adverse events

# **Supplies**

Not all supplies will be provided (e.g. IV)



# Service Rate versus Your Cost

- For industry funded studies, request full price of a service
- Difference between full cost and research rate for services can be applied to effort/personnel costs
- Any remaining funds on an industry sponsored study budget are study contingency/development funds
- Example: venipuncture CPT code 36415
  - Service rate \$26 = sponsor pays
  - Your cost \$4.42 = research team pays from study account
  - Difference \$21.58 = personnel costs/contingency funds



# **Internal Budget**

- Actual costs/activity
- Contingency Funds
- > Project Period
- > Personnel effort
- > Breakeven analysis
- Indirect cost on (almost) all costs
- Max compensation calculation (ORSP)



### **Sponsor Budget**

- Charges to sponsor
  - Mark up rolled into the charges
- No contingency (viewed as profit by a sponsor)
- > Sponsor format
  - Usually in per patient format
- Indirect costs /Overhead



- Internal versus Sponsor Budget: negotiate in sponsor budget format
  - Know your true costs and breakeven
  - Leave room to negotiate/meet in the middle
- Fair Market Value (FMV)
  - Be prepared to justify your costs
  - Justification documentation
- Providing a realistic enrollment number is key
- Review contract language (screen fails, holdback, etc.)



- Route completed budget and CTA document in ePDS for review and approval
- ORSP will review legal terms
- ORSP will notify study team when document is ready for to be signed by PI and then executed by an institutional official within ORSP



# What goes in the contract?

- Requirements for study conduct
- (c) The Principal Investigator shall be responsible for performing the Study and for the direct supervision of any individual performing any portion of the Study (the "Study Staff"). In the event one or more sub-investigators provide services under this Agreement, Institution and Principal Investigator shall ensure that each sub-investigator (i) has the experience, qualifications and capabilities to perform the Study in a timely, professional and competent manner; and (ii) agrees to comply with the terms of this Agreement and the Protocol. The Principal Investigator shall use independent medical judgment in determining the eligibility of a Study subject to participate in the Study and as to all aspects of a Study subject's medical care.
- 1.2 Study Treatment. Vertex shall provide Institution, at no cost, such quantities of the investigational drugs and other drugs as may be required for the Study (collectively, the "Study Treatment"). Institution shall safeguard the Study Treatment with the same degree of care used for its own property and in accordance with the Protocol and Applicable Law. Institution shall, following completion or termination of the Study, return or otherwise dispose of any unused Study Treatment, at Vertex's expense and in accordance with written instructions from Vertex and Applicable Law. Institution shall maintain complete and accurate drug accountability records, and shall promptly provide such records to Vertex upon request. The Study Treatment shall be used solely in conducting the Study.



# What goes in the contract?

Payment terms – what and when you will be paid

4. Payments Schedule. The start-up and administrative fee will be paid upon execution of this Agreement. All other undisputed payments will be made in accordance with the Agreement and within forty-five (45) days following the end of each calendar quarter, based upon the number of visits completed as demonstrated by completion of entry of visit data in the eCRFs/CRFs. Institution shall complete the eCRFs/CRFs within five (5) days following a visit. The final payment is conditioned upon: (a) all enrolled subjects other than subjects discontinued or lost to follow-up having completed treatment in the Study as defined in the Protocol; (b) eCRFs/CRFs and Study Records for all subject visits performed having been completed and delivered to Vertex or designated CRO; (c) all unused Study Treatment having been returned or otherwise disposed of in accordance with Vertex's instruction and Applicable Law; and (d) all queries having been resolved to Vertex's satisfaction.



# Invoicing

Develop a system for tracking all charges and events

Submit invoices for all of these items according to the time schedule outlined in the contract

Reconcile the payments with invoices on a periodic basis

Do not close the study account until you are assured you have received all payments



# Sponsor Invoicing & Receivables

### Communicate with your administrators!

- > Who is responsible for invoicing? How often?
- > Let them know when there is study activity = something to invoice
  - > IRB amendments/renewals, screen failures, shipping, unscheduled visits, etc.
  - > Recruitment

# You negotiated a contract and did the work so collect the money!!!





# **Expense Monitoring**

### Corporate Clinical Studies are contracts, not grants

- You can only spend what you earn
- > No enrollment = insufficient funds

# Effort continues on clinical studies whether patients are being enrolled or not

- Screening
- Regulatory (documentation, amendments, continuing reviews)
- > Sponsor communications

### Important to monitor your expenses in relation to your income

> When to consider closing a study?



# What if I fall behind in my revenues?

### It is possible to have a negative balance

- You are paying out charges before you have had invoices paid
- Salary is most typically attributed to the grant and may not reflect actual activity (pay attention!)

Make sure that invoices have been sent out and that payments have been reconciled

If you cannot enroll, you should stop the study



# Closing out a study

When things are not going so well When we've completed the study

- > Are you sure we're done? (queries, monitor visits, etc.)
- > Have we invoiced for EVERYTHING?
- > Have we been paid what we invoiced?

How did we do? Any contingency funds?

> What do we do with them?



# What if I have money left over?

It is possible for an industry study to realize a "profit"

- Your budget was "off" but you do not need to return the monies as you have a contract agreement with the sponsor
- Most likely because you are spending more time on the study but not charging personnel time to the grant

You can attribute additional salary to the grant, but only for those who have worked on the study (compliance issue)

After the study is closed, you may move the remaining funds (i.e. all expected charges have been paid) into a residual account

- > This may be used like any other state funds
  - Salary
  - > Travel
  - > Academic costs



# Final thoughts...

### **Budget/Contract Negotiations**

> Always negotiate

### Feasibility, Planning & Enrollment are key

- PI, Coordinator, Other research staff/experts, Data, Central office/CTO
- > Recruitment plan & execution

#### How do we define success?

- Meeting contract obligations as outlined in the contract
- > Expenses < Income = Contingency/Development funds</p>
  - > Projects with > 25% of the total project revenue may require explanation
  - http://academicdepartments.musc.edu/vpfa/policies/grants/4-4.02.htm

